Core Viewpoint - Recently, Lizhu Group released an investor research record detailing the progress of its innovative drug, Lakanqita monoclonal antibody, in the immunology field and vaccine development [1] Immunology Field - Lakanqita monoclonal antibody is the company's flagship product, currently undergoing clinical research for moderate to severe psoriasis and ankylosing spondylitis [1] - The psoriasis indication has been submitted for market approval and included in the CDE priority review, with the earliest approval expected by the end of this year [1] - The ankylosing spondylitis indication is expected to be submitted for market approval in Q2 2026 [1] - Phase III clinical research shows a PASI 100 response rate of 49.5% for the Lakanqita monoclonal antibody group, significantly better than the 40.2% response rate for Secukinumab [1] - The company has initiated overseas collaboration discussions to explore the development of new indications in the future [1] Vaccine Development - The company is advancing the development of an inactivated influenza vaccine and recombinant human follicle-stimulating hormone injection [1] - The quadrivalent recombinant protein influenza vaccine is expected to enter Phase II clinical trials in the first half of 2026 [1] - The recombinant human follicle-stimulating hormone injection is anticipated to receive market approval within 2026 [1] - The company emphasizes the continued use of AI technology to enhance research and development efficiency, shorten development cycles, and further strengthen market competitiveness [1]

Group 1: Product Development and Clinical Trials - The innovative drug Lakanqita Monoclonal Antibody targets IL-17A/F and is the first of its kind in China, with core indications for moderate to severe psoriasis and ankylosing spondylitis [2][3] - The Phase III clinical trial for psoriasis showed a PASI100 response rate of 49.5% at week 12, significantly higher than the 40.2% response rate of Secukinumab, achieving statistical superiority [2][3] - The ankylosing spondylitis indication is expected to be submitted for approval in Q2 2026, with the psoriasis indication anticipated to receive approval by the end of this year [2][3] Group 2: Market Potential and Commercial Strategy - The market potential for autoimmune skin diseases in China is substantial, with expectations for growth as the accessibility of biological agents increases [3] - The company has initiated overseas collaboration discussions and signed confidentiality agreements with potential partners to explore new indications and leverage international clinical experience [3] - A comprehensive commercial strategy is in place, including brand image development and participation in dermatology conferences to promote clinical research results [3] Group 3: Vaccine Development - The company is focusing on both therapeutic and preventive biological products, leveraging its established recombinant protein vaccine platform developed during the COVID-19 pandemic [4][5] - The quadrivalent recombinant protein influenza vaccine, the first of its kind with an adjuvant, aims to enhance immune protection, particularly for the elderly and patients with chronic diseases [5] - The influenza vaccine is expected to enter Phase II clinical trials in the first half of 2026, following successful Phase I trials [5] Group 4: Fertility Treatment Products - The recombinant human follicle-stimulating hormone injection is a key product in the assisted reproduction sector, designed for ease of use with a reusable injection pen [6] - This product is projected to be approved for market release in 2026, with growing demand anticipated in the domestic assisted reproduction market [6] Group 5: Research and Development Principles - The company has established clear and rigorous product development principles focusing on disease area specialization, technological innovation, scientific research, and commercial viability [7][8] - Emphasis is placed on differentiated innovation to avoid homogenization and build unique market advantages [8] Group 6: AI Integration in Operations - The company is implementing AI technology across its entire business chain, significantly enhancing efficiency in research and development [8] - In the development of the quadrivalent recombinant protein influenza vaccine, AI tools reduced the optimization time for processes by over 50%, achieving a fourfold increase in antigen expression and a 98% reduction in host protein impurities [8]

Group 1 - The company is in a value realization phase, leveraging its technology platforms such as sustained-release microspheres, antibody drugs, and recombinant protein vaccines for product iteration and comprehensive layout in key areas like digestive tract, assisted reproduction, and mental health [1] - Multiple drugs are at various research stages, with the monoclonal antibody Lakanqita already submitted for market approval for moderate to severe psoriasis and included in the priority review process, showing significant clinical value [1] - The company plans to acquire 64.81% of Vietnam's IMP Company by May 2025, which is expected to enhance its global commercialization strategy [1] Group 2 - Revenue forecasts for the company from 2025 to 2027 are projected at 11.977 billion, 12.028 billion, and 12.996 billion yuan, with year-on-year growth rates of 1.4%, 0.4%, and 8.1% respectively [2] - Net profit attributable to shareholders is expected to be 2.173 billion, 2.227 billion, and 2.528 billion yuan for the same period, with growth rates of 5.4%, 2.5%, and 13.5% respectively [2] - The company is rated as "overweight" with corresponding PE ratios of 14.3, 13.9, and 12.3 times based on the closing price on January 30 [2]

Core Viewpoint - The company adopts a "dual-track" strategy for its international expansion, focusing on both licensing out innovative products to mature markets and direct exports to emerging markets to establish a global sales network [1] Group 1: Licensing Strategy - The company is currently focusing on overseas rights cooperation for its core product, Lecanemab, in the self-immune field, which has attracted attention from multiple overseas pharmaceutical companies due to its clinical efficacy and low dosing frequency [1] - The partnership with XinKang allows for shared overseas rights, enhancing the product's market potential [1] Group 2: Export Strategy - The company has systematically laid out its export strategy since 2022, prioritizing Southeast Asia and South America as key emerging markets [1] - The decision is based on three core considerations: 1. Regional driving effect, using Vietnam and Brazil as pivotal points to accelerate market expansion due to their robust drug regulatory systems [1] 2. Registration synergy, as Southeast Asian countries generally recognize or can reference Chinese clinical research data, speeding up the approval process [1] 3. Market growth potential, with Vietnam's pharmaceutical market maintaining double-digit growth and Brazil being the largest pharmaceutical market in Latin America [1] Group 3: Implementation Measures - In Southeast Asia, the company is building a localized production and sales platform through the acquisition of the Vietnamese listed company IMP [1] - In South America, the focus is on Brazil, actively promoting product registration and channel development, leveraging its efficient review process to accelerate product entry [1] - The company expects that through 2-3 years of strategic layout and cultivation, its overseas formulation business will gradually scale up and contribute positively to financial performance in the future [1]

Core Viewpoint - Lijun Group's research indicates significant advancements in its biopharmaceutical platform, focusing on autoimmune, reproductive, and vaccine sectors, with key products nearing approval and promising clinical results [1][4][5] Group 1: Autoimmune Sector - Lijun Biopharmaceutical's core product, Lakanqita monoclonal antibody, shows a PASI100 response rate of 49.5% in severe psoriasis, outperforming the control group at 40.2%, and is expected to receive approval by the end of this year [1][6][7] - The company has completed Phase III clinical trials for ankylosing spondylitis, with approval anticipated next year, and significant sales growth for another product, tocilizumab, is expected in 2025 [1][4] Group 2: Reproductive Sector - The recombinant human follicle-stimulating hormone injection is expected to be approved within this year, reinforcing the company's leading position in the assisted reproductive field [1][4] Group 3: Vaccine Sector - The quadrivalent influenza recombinant protein vaccine, the first of its kind with an adjuvant, has completed Phase I safety trials and is expected to enter Phase II clinical trials in March [5] Group 4: Overseas Expansion Strategy - The company adopts a "dual-track" strategy for international expansion, focusing on licensing its innovative pipeline to mature markets and exporting formulations to emerging markets [2][9] - In Southeast Asia, the company is building a localized platform through the acquisition of IMP in Vietnam, while in South America, it is prioritizing registration and channel development in Brazil [9] Group 5: Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category in China, showing comparable efficacy to enoxaparin with a lower bleeding risk, and is preparing for Phase III trials [3][10] Group 6: GnRH Pipeline - The GnRH pipeline covers all indications and various formulations, with key products like the three-month formulation of leuprolide expected to be approved this year [11][12] Group 7: Chemical Preparation Sector - The chemical preparation sector generated 47.2 billion yuan in revenue from January to September 2025, accounting for 51.8% of the company's total revenue, serving as a core revenue support [13][14] - Future growth will be driven by product upgrades, innovative product launches, and deepening market penetration in core therapeutic areas [14][15][16]

Core Viewpoint - The company, Lizhu Group, has announced that its core product, Lakanqita monoclonal antibody, has outperformed Secukinumab in the primary endpoint of a Phase III head-to-head clinical trial for moderate to severe psoriasis, with a PASI 100 response rate at week 12 [1] Group 1 - The product is the first IL-17A/F dual-target inhibitor in China, offering advantages such as less frequent dosing, convenient administration, and excellent safety profile [1] - The company has submitted for market approval and has been included in the CDE's priority review, with the earliest expected approval by the end of 2026 [1] - Cost competitive barriers have been established through the localization of raw materials and process optimization, laying a foundation for future market access and commercialization [1]

Business Overview - Lizhu Biopharmaceuticals operates three main business segments: autoimmune, reproductive, and vaccine fields [2][3] - The core product in the autoimmune field, Lakanqita monoclonal antibody, has shown superior efficacy in clinical trials compared to competitors [4][5] Autoimmune Field - Lakanqita monoclonal antibody targets IL-17A/F dual sites, with a PASI100 response rate of 49.5% in clinical trials, outperforming the control group at 40.2% [4] - The product is expected to receive approval by the end of 2026, with significant market potential due to its unique characteristics [5] Reproductive Field - The recombinant human follicle-stimulating hormone (r-FSH) injection is anticipated to be approved within the year, reinforcing the company's leadership in assisted reproduction [3] Vaccine Field - The quadrivalent recombinant protein influenza vaccine is the first of its kind with an adjuvant, having completed Phase I trials and expected to enter Phase II in March [3] International Expansion Strategy - The company adopts a dual-track strategy for international expansion, focusing on licensing out innovative pipelines and direct exports to emerging markets [5][6] - Key markets include Southeast Asia and South America, with Vietnam and Brazil as strategic hubs for regulatory advantages and market growth [6] Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category, aimed at preventing venous thromboembolism (VTE) post-orthopedic surgeries [7] - The product has shown comparable efficacy to standard therapies and is preparing for Phase III trials [8] GnRH Pipeline - The GnRH pipeline covers all related indications and various formulations, making it the most comprehensive in China [9] - Key products include leuprolide with multiple formulations expected to launch soon, enhancing market presence [9] Chemical Preparation Segment - The chemical preparation segment generated revenue of 4.72 billion CNY, accounting for 51.8% of the company's total revenue in the first nine months of 2025 [10][11] - Growth drivers include product upgrades, innovation, and a focus on core therapeutic areas [11][12]

Group 1: Product Development and Market Positioning - The company is advancing the IL-17A/F monoclonal antibody project, targeting psoriasis and ankylosing spondylitis, with a New Drug Application (NDA) submitted for psoriasis, expected approval by Q4 2026 [2][3] - The product has received priority review status from the National Medical Products Administration (NMPA) and aims to participate in the 2027 national health insurance negotiations [2] - The company has secured production and commercialization rights for ankylosing spondylitis in China, with Phase III clinical trial data expected to be finalized by mid-2026 [2] Group 2: Competitive Advantages - The product's differentiation lies in head-to-head clinical efficacy against a positive control drug, showing superior efficacy in key indicators such as PASI100 and PASI75 [3] - Cost advantages are noted due to the localization of key materials and a lower administration frequency compared to competitors, allowing for flexible pricing strategies [3] Group 3: Target Market Strategy - The primary focus post-launch will be on new psoriasis patients, as the current penetration of biological drugs in this market is low, indicating significant growth potential [3] - The company also targets patients who do not respond well to existing IL-17A inhibitors [3] Group 4: Sales and Marketing Strategy for Aripiprazole Microspheres - Aripiprazole microspheres were launched in May 2025 and included in the 2025 health insurance directory at a price of 850 RMB per bottle, effective January 1, 2026 [4] - The company plans to leverage a nationwide psychiatric sales team and marketing network to promote the product [4] - Strategies include real-world studies to evaluate efficacy and safety, aiming for rapid market penetration in 80% of psychiatric hospitals in 2026 [4] Group 5: GnRH Product Line Development - The company has developed a comprehensive product matrix for GnRH drugs, covering all indications and offering various dosage forms [5][6] - Key products include Leuprolide and Triptorelin, with Leuprolide microspheres expected to be approved in H2 2026 for breast cancer and prostate cancer [5] - The oral GnRH antagonist is in Phase II clinical trials, showing promise for infertility treatments [5][6] Group 6: Innovation in Neurology - The company is developing NS-041, a selective potassium channel activator for epilepsy and depression, with ongoing Phase II clinical trials [7] - NS-041 aims to avoid safety risks associated with previous similar drugs and is positioned as a best-in-class candidate in the market [7]

Core Viewpoint - Lijun Pharmaceutical and Xinkanghe Biotech have submitted an application for the market approval of Lakanqita Monoclonal Antibody (LZM012/XKH004) for the treatment of plaque psoriasis [2] Group 1: Product Development - Lakanqita Monoclonal Antibody is an IL-17A/IL-17F monoclonal antibody that targets both homodimer IL-17A-A and IL-17F-F, as well as heterodimer IL-17A-F [4] - Lijun Pharmaceutical's subsidiary, Lijun Monoclonal Antibody, has exclusive rights for the global development, registration, production, sales, and sublicensing of this product [4] Group 2: Clinical Trial Results - In July, Lijun Pharmaceutical announced that Lakanqita Monoclonal Antibody (320mg, once every 4 weeks) met the primary endpoint in a Phase III clinical trial compared to Secukinumab (300mg, once every 4 weeks) for moderate to severe plaque psoriasis patients with or without psoriatic arthritis [4] - At week 12 of treatment, the proportion of patients achieving PASI 100 in the Lakanqita group was 49.5%, compared to 40.2% in the Secukinumab group, meeting both non-inferiority and superiority standards [4] - The overall safety profile of Lakanqita Monoclonal Antibody was good, with the incidence of common adverse events comparable to that of the control group [4]

Core Viewpoint - Lijun Pharmaceutical and Xinkanghe Biotech have submitted an application for the market approval of Lakanqita monoclonal antibody (LZM012/XKH004) for the treatment of plaque psoriasis [1] Group 1: Product Development - Lakanqita monoclonal antibody is an IL-17A/IL-17F monoclonal antibody that targets both homodimer IL-17A-A and IL-17F-F, as well as heterodimer IL-17A-F [2] - Lijun Pharmaceutical's subsidiary, Lijun Monoclonal Antibody, has obtained exclusive rights for the global development, registration, production, sales, and sublicensing of this product [2] Group 2: Clinical Trials - In July, Lijun Pharmaceutical announced that Lakanqita monoclonal antibody (320mg, once every 4 weeks) met the primary endpoint in a Phase III clinical trial compared to Secukinumab (300mg, once every 4 weeks) for moderate to severe plaque psoriasis patients with or without psoriatic arthritis [3] - At week 12 of treatment, the proportion of patients achieving PASI 100 in the Lakanqita group was 49.5%, compared to 40.2% in the Secukinumab group, meeting both non-inferiority and superiority standards [3] - The overall safety profile of Lakanqita monoclonal antibody was good, with the incidence of common adverse events comparable to that of the control group [3]